Karyopharm Therapeutics Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 3.19
Dividend & YieldN/A$ (N/A)
Beta -0.14
Market capitalization 411.46M
Operating cash flow -97.24M
ESG Scores unknown

Company description

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Sector: Healthcare - Industry: Biotechnology

Financial Ratios
Quick Ratio3.68
Working Capital-0.61
Return On Equity1.56
Debt To Equity-3.79
Fixed Asset Ratio2.33
Fixed Interest Cover-3.77

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities -9.41M -12.66M -771k -3.14M
Total Cashflows From Investing Activities -107.66M 78.45M -53.69M 141.84M
Net Borrowings 166.88M
Total Cash From Financing Activities 316.11M 124.31M 172.08M 73.65M
Change To Operating Activities 9.24M 7.56M 9.77M -8.97M
Issuance Of Stock 149.22M 50.7M 172.08M 13.65M
Net Income -178.41M -199.59M -196.27M -124.09M
Change In Cash 49.25M 11.95M -41.57M 108.32M
Effect Of Exchange Rate -78k 19k 268k -48k
Total Cash From Operating Activities -159.12M -190.82M -160.23M -107.12M
Depreciation 735k 974k 972k 789k
Change To Account Receivables -7.86M -7.86M -5.02M -9.62M
Other Cashflows From Financing Activities 73.61M 73.61M 60M 60M
Change To Netincome 17.3M 13.91M 25.64M 38.59M
Capital Expenditures -2.36M -206k -145k -212k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 6.41M 6.41M 10.21M 11.84M
Income Before Tax -178.38M -199.55M -195.96M -123.82M
Net Income -178.41M -199.59M -196.27M -124.09M
Selling General Administrative 48.85M 105.42M 126.42M 143.85M
Gross Profit -131.04M -77.45M -35.22M 57.42M
Ebit -179.88M -189.28M -171.85M -98.27M
Operating Income -179.88M -189.28M -171.85M -98.27M
Interest Expense -2.49M -15.65M -27.14M -26.05M
Income Tax Expense 26k 40k 309k 268k
Total Revenue 30.34M 40.89M 108.08M 209.82M
Cost Of Revenue 161.37M 118.34M 143.3M 152.4M
Total Other Income ExpenseNet 1.5M -10.28M -24.11M -25.55M
Net Income From Continuing Ops -178.41M -199.59M -196.27M -124.09M
Net Income Applicable To Common Shares -178.41M -199.59M -196.27M -124.09M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 158.02M 245.19M 262.5M 384.98M
Total Stockholder Equity 183.17M 49.77M 50.55M -79.67M
Other Current Liabilities 10.08M 2.84M 906k 678k
Total Assets 341.19M 294.96M 313.05M 305.31M
Common Stock 6k 7k 7k 8k
Other Current Assets 1.12M 2.48M 6.35M
Retained Earnings -673.75M -873.34M -1.07B -1.18B
Treasury Stock -244k -37k 518k 191k
Cash 118.02M 128.86M 85.92M 190.46M
Total Current Liabilities 46.9M 46.35M 60.2M 73.72M
Other Stockholder Equity -244k -37k 518k 191k
Property, Plant, and Equipment 3.86M 13.66M 11.58M 9.56M
Total Current Assets 334.61M 278.57M 276.53M 275.61M
Net Tangible Assets 183.17M 49.77M 50.55M -79.67M
Net Receivables 7.86M 12.88M 22.5M
Accounts Payable 4.33M 985k 4.45M 1.6M


Insider Transactions

Here are the insider transactions of stock shares related to Karyopharm Therapeutics Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
PAULSON RICHARD A.Sale at price 4.54 per share.D2022-11-04Chief Executive Officer3.49k
PAULSON RICHARD A.Sale at price 5.87 per share.D2022-10-04Chief Executive Officer3.49k
PAULSON RICHARD A.Sale at price 5.23 - 5.26 per share.D2022-09-08Chief Executive Officer3.48k
MASON MICHAEL PStock Award(Grant) at price 0.00 per share.D2022-08-31Chief Financial Officer30k
MITCHENER STEPHENStock Award(Grant) at price 0.00 per share.D2022-08-31Officer20k
MANO MICHAELStock Award(Grant) at price 0.00 per share.D2022-08-31General Counsel20k
CHENG SOHANYA ROSHANStock Award(Grant) at price 0.00 per share.D2022-08-31Officer30k
GREENE BARRY EConversion of Exercise of derivative security at price 1.48 per share.D2022-08-11Director7.58k
PAULSON RICHARD A.Sale at price 4.48 per share.D2022-08-04Chief Executive Officer2.31k
PAULSON RICHARD A.Sale at price 5.18 per share.D2022-07-08Chief Executive Officer2.12k
CHENG SOHANYA ROSHANSale at price 5.20 - 5.34 per share.D2022-06-13Officer1.55k
PAKIANATHAN DEEPIKA R PH.D.Sale at price 6.00 - 6.50 per share.I2022-06-10Director538.78k
PAULSON RICHARD A.Sale at price 5.76 per share.D2022-06-07Chief Executive Officer2.54k
MASON MICHAEL PSale at price 6.04 - 6.07 per share.D2022-06-03Chief Financial Officer601
PAULSON RICHARD A.Sale at price 6.23 - 6.26 per share.D2022-05-04Chief Executive Officer28.5k
RANGWALA RESHMAStock Award(Grant) at price 0.00 per share.D2022-04-29Officer65k
SHACHAM SHARONStock Award(Grant) at price 0.00 per share.D2022-03-29Officer60k
KAUFFMAN MICHAEL GStock Award(Grant) at price 0.00 per share.D2022-02-28Director21k
KAUFFMAN MICHAEL GSale at price 10.24 per share.D/I2022-02-28Director12.45k
MASON MICHAEL PStock Award(Grant) at price 0.00 per share.D2022-02-28Chief Financial Officer88.2k
MASON MICHAEL PSale at price 10.24 per share.D2022-02-28Chief Financial Officer2.4k
SHACHAM SHARONStock Award(Grant) at price 0.00 per share.I2022-02-28Officer21k
SHACHAM SHARONSale at price 10.24 per share.D/I2022-02-28Officer12.45k
FRENKEL RANStock Award(Grant) at price 0.00 per share.D2022-02-28Officer68.25k
FRENKEL RANSale at price 10.24 per share.D2022-02-28Officer1.66k
MITCHENER STEPHENStock Award(Grant) at price 0.00 per share.D2022-02-28Officer47.25k
PAULSON RICHARD A.Stock Award(Grant) at price 0.00 per share.D2022-02-28Chief Executive Officer288.75k
MANO MICHAELStock Award(Grant) at price 0.00 per share.D2022-02-28General Counsel63k
CHENG SOHANYA ROSHANStock Award(Grant) at price 0.00 per share.D2022-02-28Officer84k
KAUFFMAN MICHAEL GSale at price 12.12 per share.D/I2022-02-17Director18.17k
SHACHAM SHARONSale at price 12.12 per share.D/I2022-02-17Officer18.17k
FRENKEL RANSale at price 12.12 per share.D2022-02-17Officer2.93k
SHAH JATINSale at price 12.12 per share.D2022-02-17Officer1.31k
KAUFFMAN MICHAEL GSale at price 9.86 per share.D/I2022-02-07Director13.47k
MASON MICHAEL PSale at price 9.86 per share.D2022-02-07Chief Financial Officer3.95k
SHACHAM SHARONSale at price 9.86 per share.D/I2022-02-07Officer13.47k
FRENKEL RANSale at price 9.86 per share.D2022-02-07Officer1.99k
SHAH JATINSale at price 9.86 per share.D2022-02-07Officer1.7k
MITCHENER STEPHENSale at price 6.69 per share.D2021-12-02Officer499
CHENG SOHANYA ROSHANStock Award(Grant) at price 0.00 per share.D2021-06-30Officer7.5k
MITCHENER STEPHENSale at price 9.29 per share.D2021-06-02Officer528
MASON MICHAEL PStock Award(Grant) at price 0.00 per share.D2021-06-01Chief Financial Officer5.5k
MITCHENER STEPHEND2021-05-28Officer1.5k
SHAH JATINPurchase at price 8.60 per share.D2021-05-07Officer23.25k
BOHLIN GAREN G.Purchase at price 7.82 per share.D2021-05-06Director4k
PAULSON RICHARD A.Stock Award(Grant) at price 0.00 per share.D2021-05-03Chief Executive Officer373.2k
KAUFFMAN MICHAEL GSale at price 12.39 per share.D2021-03-18Chief Executive Officer4k
SHACHAM SHARONSale at price 12.39 per share.I2021-03-18President4k
KAUFFMAN MICHAEL GStock Award(Grant) at price 0.00 per share.D/I2021-02-25Chief Executive Officer114.4k
LEWIS TANYAStock Award(Grant) at price 0.00 per share.D2021-02-25Officer22.01k
MASON MICHAEL PStock Award(Grant) at price 0.00 per share.D2021-02-25Chief Financial Officer22.01k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Karyopharm Therapeutics Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Karyopharm Therapeutics Inc

Here is the result of two systematic investment strategies applied to Karyopharm Therapeutics Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Karyopharm Therapeutics Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Karyopharm Therapeutics Inc:

Karyopharm Therapeutics Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -31.87% on the backtest period.

Performance at glance

Performance

-31.87 %

Latent gain

-554.66 $

Invested capital

1740.47 $

Annualized return

-7.77 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Karyopharm Therapeutics Inc

This is the result of two momentum investment strategies applied to Karyopharm Therapeutics Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Karyopharm Therapeutics Inc

The following chart shows all the entries opened by the momentum investment system on Karyopharm Therapeutics Inc:

Karyopharm Therapeutics Inc momentum entries
  • The first momentum investment strategy would give -26.2% of return on Karyopharm Therapeutics Inc. That represents -1313.4$ of latent gain with 5013.8$ of employed capital.
  • The second momentum investment strategy would give -31.44% of return on Karyopharm Therapeutics Inc. That represents -1341.9$ of latent gain with 4268.58$ of employed capital.
Performance at glance (1Q Momentum)

Performance

-26.2 %

Latent gain

-1313.4 $

Invested capital

5013.8 $

Annualized return

-15.55 %
Performance at glance (2Q Momentum)

Performance

-31.44 %

Latent gain

-1341.9 $

Invested capital

4268.58 $

Annualized return

-8.69 %

Momentum equity curve on Karyopharm Therapeutics Inc

The following chart shows the equity curve of the two momentum strategies applied to Karyopharm Therapeutics Inc:

Karyopharm Therapeutics Inc momentum equity

Note: the dividends potentially given by Karyopharm Therapeutics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Karyopharm Therapeutics Inc

The following chart shows the employed capital evolution of the two momentum strategies on Karyopharm Therapeutics Inc since the beginning:

Karyopharm Therapeutics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Karyopharm Therapeutics Inc

Buy the dip entry openings on Karyopharm Therapeutics Inc

Karyopharm Therapeutics Inc

The performance achieved by the robo-advisor on Karyopharm Therapeutics Inc is -32.66%. That represents -485.44$ of latent gain with 1486.23$ of employed capital. The following chart shows Karyopharm Therapeutics Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Karyopharm Therapeutics Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

-32.66 %

Latent gain

-485.44 $

Invested capital

1486.23 $

Annualized return

-15.55 %

Equity curve of the strategy applied to Karyopharm Therapeutics Inc

The following chart shows the result of the investment strategy applied to Karyopharm Therapeutics Inc:

Karyopharm Therapeutics Inc

Note: the dividends potentially given by Karyopharm Therapeutics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Karyopharm Therapeutics Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Karyopharm Therapeutics Inc:

Karyopharm Therapeutics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Karyopharm Therapeutics Inc

In this section, I will compare the three previous investment strategies applied to Karyopharm Therapeutics Inc.

Equity curve comparison on Karyopharm Therapeutics Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Karyopharm Therapeutics Inc investment strategy comparison

Employed capital comparison on Karyopharm Therapeutics Inc

Karyopharm Therapeutics Inc investment comparison

Performance comparison on Karyopharm Therapeutics Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -31.87% -554.66$ 1740.47$ -7.77%
Momentum 1 quarter -26.2% -1313.4$ 5013.8$ -6.79%
Momentum 2 quarters -31.44% -1341.9$ 4268.58$ -8.69%
Non-directional -32.66% -485.44$ 1486.23$ -15.55%
Annualized return comparison

Automatic investment

-7.77 %

Momentum 1Q

-8.69 %

Momentum 2Q

-8.69 %

Non-directional

-15.55 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Karyopharm Therapeutics Inc:

Positive correlations

Most correlated stocks this year

  • Karyopharm Therapeutics Inc

  • Most correlated stocks last 3 months

  • Karyopharm Therapeutics Inc

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months

  • American Financial Group Inc

  • Note: The algorithm computes the probability of correlation between Karyopharm Therapeutics Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Karyopharm Therapeutics Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name Karyopharm Therapeutics Inc
    Country United States
    City Newton
    Address 85 Wells Avenue
    Phone 617 658 0600
    Website www.karyopharm.com
    FullTime employees 442
    Industry Biotechnology
    Sector Healthcare
    Exchange XNAS
    Ticker KPTI
    Market www.nasdaq.com

    Karyopharm Therapeutics Inc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown